China Bioengineering (01237.HK) announces interim results with a net profit attributable to shareholders of 8.752 million yuan, reversing from a loss to a profit year-on-year.

date
30/08/2025
Wisdom Finance APP News, China Science Biology (01237.HK) announced its mid-term performance for 2025, with revenue of 199.5 million RMB, a year-on-year increase of 6.98%; shareholders' attributable profit was 8.752 million RMB, compared to a loss of 1.715 million RMB in the same period last year, turning the loss into profit year-on-year; basic earnings per share was 0.095 yuan.